Axsome Therapeutics Presents New AUVELITY® Data in Major Depressive Disorder at the American Society of Clinical Psychopharmacology (ASCP) 2026 Annual Meeting
Axsome Therapeutics is presenting four posters at the ASCP 2026 Annual Meeting in Miami, focusing on new data for its lead asset AUVELITY. Three presentations cover AUVELITY’s effects in major depressive disorder, including anxious distress subgroups, post-hoc anxiolytic analyses, and real-world outcomes for patients switching to treatment.
Key figures
- Drug Name
- AUVELITY (dextromethorphan-bupropion)
- Meeting
- ASCP 2026 Annual Meeting
- Presentation count
- 4
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.